Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Small interfering RNA (siRNA) Therapeutics Market Research Report 2016

Wednesday, November 16, 2016 0:03
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Global Small interfering RNA (siRNA) Therapeutics Market

The Report, “Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2016” depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.

Try Sample Report @

This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.

There are 15+ active companies dealing with 85+ siRNA therapies. Mostly siRNA is being studied for oncology area with 27 siRNA therapies under development by major pharma companies followed by 14 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology. Currently 23 siRNA are in clinical stage of development with many mid-stage products.

§ Coverage of global siRNA therapies under development across the globe 
§ Competitive landscape of investigational products for key players and key therapy areas 
§ The new siRNA report includes emerging technologies, drivers, barriers and eminent therapy areas focused by major companies. 
§ Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information. 
§ Report has highlighted the major collaborations, deals and acquisitions done by pharma companies to enrich their siRNA pipeline. 
§ Report analyzes the different emerging delivery technologies by companies and products under development.

Access Complete Report @

Reason to Buy 
§ The siRNA report covers complete Pipeline intelligence and understanding over therapeutics development for siRNA. 
§ Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
§ Identify and understand important and diverse types of therapeutics under development for siRNA 
§ The siRNA report helps to develop a better understanding of the emerging technologies by the recent acquisitions which are driving the siRNA market 
§ Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
§ Devise corrective measures for pipeline projects by understanding siRNA pipeline in-depth 
§ Identifying the upcoming leaders in the siRNA market in the coming year

Table of contents: 
Executive Summary 
Small interfering RNA (siRNA) Therapeutics Overview 
Historical Development: 
siRNA: Mode of Action 
siRNA Technology &Delivery methods 
SiRNA & its Applications in Gene Silencing: 
Commercial Assessment 
siRNA Therapeutics: Technology Analysis 
siRNA Technology & Companies Current Scenario 
Companies & Technologies 
siRNA Technologies & Products 
siRNA Therapeutics: Collaborations Analysis 
siRNA Theraputics Collaborations & Deals 
siRNA Therapeutics Licensing Deals: 
siRNA Therapeutics Acquisition Deals 
siRNA Therapeutics: Pipeline Analysis 
siRNA Theraputics Therapy Area Analysis 
siRNA Therpeutics Clinical Trials Analysis 
siRNA Therapeutics &USFDA/EMA Designations 
Pipeline Overview 
Last Stage Products (Phase III) 
Comparative Analysis 
Mid Stage Products (Phase II) 
Comparative Analysis 
Early Stage Products (Phase I and IND) 
Comparative Analysis 
Pre-Clinical and Discovery Products 
Comparative Analysis 
Therapeutic Assessment 
Assessment by Monotherapy Products 
Assessment by Combination Products 
Assessment by Route of Administration 
Discontinued Products 
Dormant Products 
Companies involved in Therapeutics Development 
Consulting Services 
About DelveInsight 
Contact Us 

List of tables:

 Table 1: siRNA Technology with delivery methods, 2016 
Table 2: siRNA therapeutics collaboration and deal value, 2016 
Table 3: siRNA therapeutics Technology Licensing Technology Licensing by Year, 2016 
Table 4: siRNA therapeutics acquisition and deal year, 2016 
Table 5: Number of Products under Development for Small interfering RNA (siRNA) Therapeutics, 2016 
Table 6: Number of Products under Development by Companies, 2016 
Table 7: Last Stage Products (Phase III), 2016 
Table 8: Mid Stage Products (Phase II), 2016 
Table 9: Early Stage Products (Phase I and IND), 2016 
Table 10: Pre-Clinical and Discovery Products, 2016 
Table 11: Assessment by Monotherapy Products, 2016 
Table 12: Assessment by Route of Administration, 2016 
Table 13: Assessment by Stage and Route of Administration, 2016 
Table 14: Discontinued Products, 2016 
Table 15: Dormant Products, 2016

List of figures: 

Figure 1: Number of technology associated with the companies, 2016 
Figure 3: Number of collaborations with year, 2016 
Figure 4: Number of products by therapy area, 2016 
Figure 5: Number of products by therapy area & Phases, 2016 
Figure 6: Number of products with ongoing and completed clinical trials, 2016 
Figure 7: Number of products in clinical trials with companies, 2016 
Figure 8: Number of products with designations, 2016 
Figure 9: Number of Products under Development for Small interfering RNA (siRNA) Therapeutics, 2016 
Figure 10: Last Stage Products (Phase III), 2016 
Figure 11: Mid Stage Products (Phase II), 2016 
Figure 12: Early Stage Products (Phase I and IND), 2016 
Figure 13: Pre-Clinical and Discovery Products, 2016 
Figure 14: Assessment by Monotherapy Products, 2016

Buy Report @

For more information or any query mail at

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn:

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.